Zynerba launches the Phase 2 trial of its Zygel CBD gel to treat 22q genetic condition - Proactive Investors USA & Canada

Zynerba launches the Phase 2 trial of its Zygel CBD gel to treat 22q genetic condition  Proactive Investors USA & Canada

Zynerba Pharmaceuticals (NASDAQ:ZYNE) - The disorder is caused by a small missing piece of the 22nd chromosome that can affect every system in the body.



Comments

Popular posts from this blog

Inside Ontario’s ‘scary’ child-welfare system where kids are ‘commodities’ - Global News

Ebstein's Anomaly: Symptoms, Causes, and Treatments - Verywell Health

Woodstock, Ont. OB-GYN used improperly sterilized medical equipment, health unit says - Global News